This article was originally published in Start Up
Pathogenica, co-founded by Harvard's George Church, PhD, views itself as an "apps" company for a variety of human genome sequencing platforms. Its BioDetection system has the potential to screen thousands of samples, each tested for hundreds of unique pathogen strains at a predicted cost of less than one dollar per pathogen. The start-up aims to enable effective and affordable pathogen sequencing in a wide range of markets - physician, veterinary, and farming - not just scientific.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.